Hydrocortisone: Clinical Trials

46 trials of Hydrocortisone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 6 terminated, 3 active not recruiting, 3 recruiting. 46 Phase 1, 16 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 146Completed 29, Terminated 6, Active not recruiting 3, Recruiting 3, Withdrawn 3, Not yet recruiting 1, Unknown 1
Phase 216Completed 7, Terminated 5, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1

Follow Hydrocortisone: new trials by email Literature Review of Hydrocortisone trials Research Report on Hydrocortisone

Trials (filtered) newest first · largest first

All 46 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 1WithdrawnChildren's Oncology Group2026-09-102026-05-05
GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy
Hydrocortisone, Pancreatic resection - Pancreatic Cancer, Pancreatic Adenocarcinoma
Phase 1Not yet recruitingUniversity of Illinois at Chicago202026-09-012026-09-01
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Phase 1 / Phase 2RecruitingNovartis Pharmaceuticals502026-07-052026-11-12
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome
Phase 1RecruitingChildren's Oncology Group362025-02-042026-08-25
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
Opevesostat, Dexamethasone, Fludrocortisone - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Phase 1CompletedMerck Sharp & Dohme LLC142024-01-302026-03-19
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
Opevesostat, Dexamethasone, Fludrocortisone acetate - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Phase 1CompletedMerck Sharp & Dohme LLC72023-11-142026-04-27
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Phase 1 / Phase 2WithdrawnChildren's Oncology Group2023-08-012023-09-01
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary
Phase 1Active not recruitingAndrew E. Place, MD142023-03-292026-11-18
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML
Phase 1RecruitingTherapeutic Advances in Childhood Leukemia Consortium542022-11-112024-12-06
HAT for the Treatment of Sepsis Associated With NASTI
HAT, Placebo - Necrotizing Soft Tissue Infection, Sepsis
Phase 1 / Phase 2TerminatedAscension Health102021-09-102024-07-24
Glucocorticoid Administration After Traumatic Birth
Intravenous (IV) hydrocortisone - Traumatic Birth
Phase 1CompletedUniversity of Michigan1332021-05-212022-11-09
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Azacitidine, Cytarabine, Fludarabine Phosphate - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Phase 1CompletedNational Cancer Institute (NCI)122019-05-172025-04-13
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Palbociclib, Cytarabine, Methotrexate - Leukemia, Lymphocytic, Lymphoblastic Lymphoma
Phase 1CompletedChildren's Oncology Group122019-04-112025-03-21
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
Pevonedistat, Vincristine, Dexamethasone - Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Phase 1CompletedJulio Barredo, MD62019-03-252022-10-20
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Ixazomib, Vincristine, Dexamethasone - ALL, Childhood, Lymphoblastic Lymphoma, Childhood
Phase 1 / Phase 2Active not recruitingTherapeutic Advances in Childhood Leukemia Consortium242019-02-122025-06-17
A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects
Infacort®, Cortef® - Adrenal Insufficiency
Phase 1CompletedNeurocrine UK Limited512018-04-162026-09-14
A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects
Chronocort®, Cortef® - Adrenal Insufficiency
Phase 1CompletedNeurocrine UK Limited252018-02-192026-09-14
Hormonal Mechanisms of Sleep Restriction - Axis Study
Ketoconazole Pill, Ganirelix, Dexamethasone - Sleep Restriction
Phase 1Active not recruitingPeter y. Liu802017-05-082025-09-11
Physiologic Effects of Steroids in Cardiac Arrest
Methylprednisolone; hydrocortisone, Saline Placebo - Inhospital Cardiac Arrest
Phase 1 / Phase 2CompletedUniversity of Athens1002016-11-042021-11-23
Investigating the Central and Peripheral Mechanisms by Which Glucocorticoids Affect Hunger
hydrocortisone, saline - Obesity
Phase 1CompletedYale University282016-05-012022-05-25

Showing 20 of 46. Sign in to see all of them.

Conditions studied

Precursor Cell Lymphoblastic Leukemia-Lymphoma (12)  ·  Leukemia, Myeloid, Acute (5)  ·  Recurrence (5)  ·  Adrenal Insufficiency (4)  ·  Leukemia, Biphenotypic, Acute (4)  ·  Prostatic Neoplasms (4)  ·  Adrenal Hyperplasia, Congenital (3)  ·  Leukemia (3)  ·  Burkitt Lymphoma (2)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, T-Cell (2)  ·  Myelodysplastic Syndromes (2)  ·  Pain (2)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Addison Disease (1)

Sponsors

Neurocrine UK Limited (7)  ·  Children's Oncology Group (5)  ·  Therapeutic Advances in Childhood Leukemia Consortium (4)  ·  Merck Sharp & Dohme LLC (2)  ·  National Cancer Institute (NCI) (2)  ·  X-pert Med GmbH (2)  ·  Amgen (1)  ·  Andrew E. Place, MD (1)  ·  Ascension Health (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Cairo University (1)  ·  Cristcot LLC (1)  ·  Dana-Farber Cancer Institute (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Haukeland University Hospital (1)

Countries

United States (28)  ·  Australia (7)  ·  United Kingdom (4)  ·  Canada (3)  ·  France (3)  ·  Germany (2)  ·  Greece (2)  ·  Israel (2)  ·  Netherlands (2)  ·  Norway (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Argentina (1)  ·  Austria (1)  ·  Brazil (1)

Top investigators

Elizabeth Raetz, MD (3)  ·  A Koch (2)  ·  Abbot R. Laptook, MD (1)  ·  Abhik Das, PhD (1)  ·  Adam Lamble, MD (1)  ·  Alexandra M Stevens (1)  ·  Andrew E Place, MD, PhD (1)  ·  Aslam Ejaz, MD (1)  ·  Barbara J. Stoll, MD (1)  ·  Barbara Pro, MD (1)  ·  Beau J. Batton, MD (1)  ·  Ben K Watkins (1)  ·  Brenda P. Poindexter, MD MS (1)

Results publications

PMID 19638218, PMID 22336574, PMID 23650301, PMID 24276047, PMID 26567120, PMID 27038920, PMID 35652112, PMID 36215217, PMID 37172949, PMID 37553297, PMID 38237077, PMID 41586417, PMID 42234929, PMID 42376206

NIH funding

U10CA098543 (2), UM1CA228823 (2), 2014 (1), 2025 (1), F31DA040369 (1), P30CA016056 (1), P30CA060553 (1), R01DK020495 (1), U10CA180886 (1), U10HD021364 (1), U10HD021373 (1), U10HD021385 (1), U10HD027851 (1), U10HD027853 (1), U10HD027856 (1)